Altoida’s artificial intelligence (AI)-powered device, intended to indicate the start of Alzheimer’s disease in adults with mild dementia but no evident disease symptoms, has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The non-invasive device uses a software that measures and monitors neurocognitive function to diagnose and distinguish Alzheimer’s disease from other disorders. These include mild cognitive impairment (MCI), a neurological disorder marked by subtle changes in memory and considered a risk…
You must be logged in to read/download the full post.
The post Device to Spot Alzheimer’s Onset in Adults Recognized by FDA appeared first on BioNewsFeeds.